Added to YB: 2026-09-21
Pitch date: 2026-09-17
NVO [bullish]
Novo Nordisk A/S
-0.6%
current return
Author Info
Kontra Invest is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.2T
Pitch Price
DKK 43.50
Price Target
370.00 (+756%)
Dividend
4.19%
EV/EBITDA
7.59
P/E
10.66
EV/Sales
4.04
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk ($NVO) ahead of CMD: the doubling thesis and a broader pipeline
NVO: Novo Nordisk offers a cautious recovery case: the Wegovy pill’s 4.1x reported prescription lead over Foundayo could persist longer than headline growth rates imply, while CagriSema, zenagamtide and efruxifermin broaden the pipeline. At DKK 278, the shares trade below 13.5x 2027 consensus EPS; a DKK 370 target implies 17.1x and 30% upside, but requires profitable oral growth and pipeline execution, with an illustrative downside case of DKK 234.
Read full article (10 min)